Edition:
United Kingdom

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

8.14USD
13 Aug 2018
Change (% chg)

$0.01 (+0.12%)
Prev Close
$8.13
Open
$8.25
Day's High
$8.41
Day's Low
$8.09
Volume
304,382
Avg. Vol
340,619
52-wk High
$9.41
52-wk Low
$5.03

Select another date:

Mon, Jul 30 2018

FDA approves Progenics' treatment for rare adrenal gland tumors

The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use.

UPDATE 1-FDA approves Progenics' treatment for rare adrenal gland tumors

July 30 The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use.

FDA approves Progenics' treatment for two rare tumors

July 30 The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of tumors.

BRIEF-Progenics Pharmaceuticals Announces Q1 Loss Per Share $0.19

* PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Progenics Says FDA Will Extend Review Of NDA For Azedra By Three Months

* PROGENICS PHARMACEUTICALS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR AZEDRA (IOBENGUANE I 131)

Select another date: